In conclusion, our findings, combined with the work of others, suggest that RAD51 expression levels could be a clinically informative prognostic biomarker for GBM patients; this finding may offer additional prognostic value in addition to other established prognostic indicators (IDH mutation and MGMT promoter methylation). The gene discussed is IDH1; the disease is glioblastoma.